The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry

January 15, 2025 updated by: Eric Topol, MD, Scripps Translational Science Institute
By creating a neurogenebank from Parkinson's disease patients' blood donations we will ultimately be able to define genes for Parkinson's disease and other neurological conditions.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • La Jolla, California, United States, 92037
        • Scripps Translational Science Institute
      • La Jolla, California, United States, 92037
        • The Scripps Research Institute
      • La Jolla, California, United States, 92037
        • Scripps Clinic, Torrey Pines

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients 30 years of age or older with the diagnosis idiopathic Parkinson's disease

Description

Inclusion Criteria:

  • Is age 30 years or older at the time of onset of Parkinson's
  • Has been diagnosed with idiopathic Parkinson's Disease by a Scripps Neurologist
  • Is reliable, cooperative and willing to comply with all protocol-specified procedures and/or sub-study if consented or have legal representative/guardian willing to do so
  • Able to understand and grant informed consent or have a legal representative/ guardian who is able to do so

Exclusion Criteria:

  • Patient has been previously enrolled in The Parkinson's Disease NeuroGenebank at Scripps Clinic Registry
  • If a blood draw would be contraindicated for any reason
  • Has a significant chronic medical condition (i.e. CVA, hepatic encephalopathy) which, in the investigator's option, may interfere with the patient's optimal participation in the study
  • Treatment with any investigational agents or devices within 30 days preceding enrollment in the study
  • Has undergone ECT within 90 days preceding enrollment in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
No Treatment
Other: There is no intervention, this is a biorepository.
There are no interventions in this study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Neurogenetic databank
Time Frame: Study completion
initiate a Parkinson's disease neurogenetic databank by obtaining blood samples in order to define genes for Parkinson's disease and other neurological conditions.
Study completion

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Scripps Translational Science Institute

Collaborators

Scripps Health
The Scripps Research Institute

Investigators

  • Principal Investigator: Cinnamon Bloss, PhD, Scripps Translational Science Institute and Genomic Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2008

Primary Completion (Estimated)

August 1, 2030

Study Completion (Estimated)

August 1, 2030

Study Registration Dates

First Submitted

October 2, 2008

First Submitted That Met QC Criteria

October 2, 2008

First Posted (Estimated)

October 6, 2008

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 15, 2025

Last Verified

January 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HSC# 08-5022

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Parkinson's Disease

Clinical Trials on There is no intervention, this is a biorepository.

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe